Corcept Therapeutics reported that relacorilant, an oral selective glucocorticoid receptor antagonist, reduced risk of death by 35% in a Phase 3 study for platinum‑resistant ovarian cancer, meeting overall survival and supporting an FDA review pathway. The result follows earlier progression‑free survival success and provides momentum ahead of a pending PDUFA date. Investors reacted to the data with a notable share bounce; analysts project substantial market potential if approved for this hard‑to‑treat population. Corcept framed the result as clinically meaningful for a disease with limited options, and the company plans to press regulatory discussions informed by the OS outcome.